A randomized, placebo-controlled trial of creatine in children with spinal muscular atrophy

Journal of Clinical Neuromuscular Disease

Volumn 8, Issue 3, 2007, Pages 101-110

  Wong, Brenda L ^a   Hynan, Linda S ^b   Iannaccone, Susan T ^c,d   Iannaccone, S T ^e   Rabb, K ^e   Carman, D ^e   Harris, K ^e   Morton, A ^e   Hynan, L S ^b   Reisch, J S ^b   Smith, J ^b   Webster, J C ^b   Goldsmith, C ^b   Gorman, A R ^b   Schochet, P N ^b   Luckett, P M ^b   Walters, P ^b   Wong, B L ^a   Samaha, F J ^a   Fritch, A ^a   Morehart, P J ^a   Russman, B S ^f   Zilke, K ^f   Sienko Thomas, S ^f   Leshner, R T ^g   Mayhew, J ^g   Grillo, B ^g   Smith, S A ^h   Stout, J ^h   Nugent, A ^h   Parke, J T ⁱ   Clark, A ⁱ   Earnest, C P ⁱ   Kryscio, R J ⁱ   Timberman, L ^j   Moy, C S ^j   Newton, C ^j   more..

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d CHILDREN S MEDICAL CENTER   (United States)

^e TEXAS SCOTTISH RITE HOSPITAL FOR CHILDREN   (United States)

^f SHRINERS HOSPITAL FOR CHILDREN   (United States)

^g Children's Hospital   (United States)

^h GILLETTE CHILDREN'S SPECIALTY HEALTHCARE   (United States)

ⁱ Data and Safety Monitoring Committee

^j Data and Safety Monitoring Committee ^*

more..

Author keywords

Creatine; Spinalmuscular atrophy (SMA)

Indexed keywords

CREATININE; PLACEBO;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTIONAL ASSESSMENT; GROSS MOTOR FUNCTION; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; MUSCLE FUNCTION; MUSCLE STRENGTH; PARENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPINAL MUSCULAR ATROPHY; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 34247629648     PISSN: 15220443     EISSN: 15371611     Source Type: Journal    
DOI: 10.1097/CND.0b013e3180315c99     Document Type: Article

References (31)

1. Pearn JH. Incidence, prevalence and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet. 1978;15:409-413.
2. Pearn JH, Bundey S, Carter CO, et al. A genetic study of subacute and chronic spinal muscular atrophy in childhood. J Neuro Sci. 1978;37:227-248.
3. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med. 1999;5:347-350.
4. Derave W, Van Den Bosch L, Lemmens G, et al. Skeletal muscle properties in a transgenic mouse model for amyotrophic lateral sclerosis: effects of creatine treatment. Neurobiol Dis. 2003;13:264-272.
5. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve. 1997;20:1502-1509.
6. Walter MC, Lochmuller H, Reilich P, et al. Creatine monohydrate in muscular dystrophies: A double-blind placebo-controlled clinical study. Neurology. 2000;54:1848-1850.
7. Tarnopolsky MA, Mahoney DJ, Vajsar J, et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology. 2004;62:1771-1777.
8. Louis M, Lebacq J, Poortmans JR, et al. Beneficial effects of creatine supplementation in dystrophic patients. Muscle Nerve. 2003;27:604-610.
9. Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology. 1999;52:854-857.
10. Mihic S, MacDonald JR, McKenzie S, et al. Acute creatine loading increases fat-free mass, but does not affect blood pressure, plasma creatinine, or CK activity in men and women. Med Sci Sports Exerc. 2000;32:291-296.
11. Tarnopolsky MA, MacLennan DP. Creatine monohydrate supplementation enhances highintensity exercise performance in males and females. Int J Sport Nutr Exerc Metab. 2000;10:452-463.
12. Bessman SP, Carpenter CL. The creatine-creatine phosphate energy shuttle. Annu Rev Biochem. 1985;54:831-862.
13. Bessman SP, Savabi F. The role of the phosphocreatine energy shuttle. In: Taylor AW, Gollnick PD, Green HJ, et al, eds. Biochemistry of Exercise. Volume 8. Champaign: Human Kinetics; 1990:167-178.
14. Bessman SP, Geiger PJ. Transport of energy in muscle: the phosphorylcreatine shuttle. Science. 1981;211:448-452.
15. Bessman SP. The physiological significance of the creatine phosphate shuttle. Adv Exp Med Biol. 1986;194:1-11.
16. Bessman SP. The creatine phosphate energy shuttle - the molecular asymmetry of a "pool." Anal Biochem. 1987;161:519-523.
17. Wallimann T, Wyss M, Brdiczka D, et al. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the "phosphocreatine circuit" for cellular energy homeostasis. Biochem J. 1992;281:21-40.
18. Matthews RT, Yang L, Jenkins B, et al. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci. 1998;18:156-163.
19. O'Gorman E, Beutner G, Wallimann T, et al. Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart and brain. Biochim Biophys Acta. 1996;1276:161-170.
20. 2+ handling and survival in mdx skeletal muscle cells. FEBS. 1998;439:357-362. Letter.
21. Lawler JM, Barnes WS, Wu G, et al. Direct antioxidant properties of creatine. Biophys Res Commun. 2002;290:47-52.
22. Iannaccone ST, Hynan LS, American Spinal Muscular Atrophy Randomized Trials (AmSMART) group. Reliability of 4 outcome measures in pediatric spinal muscular atrophy. Arch Neurol. 2003;60:1130-1136.
23. Iannaccone ST, AmSMART group. Outcome measures for pediatric spinal muscular atrophy. Arch Neurol. 2002;59:1445-1450.
24. Mallinckrodt CH, Kaiser CJ, Watkin JG, et al. The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA. Clin Trials. 2004;1:477-489.
25. Groeneveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol. 2003;53:437-445.
26. Shefner JM, Cudkowicz ME, Schoenfeld D, et al. NEALS consortium. A clinical trial of creatine in ALS. Neurology. 2004;63:1656-1661.
27. Osterberg R, Green M. Guidance for industry and reviewers: estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers. Rockville, MD: US Department of Health and Human Services, Center for Drug Evaluation and Research, 2002.
28. Iannaccone ST, Russman BS, Browne RH, et al. Prospective analysis of strength in spinal muscular atrophy. J Child Neurol. 2000;15:97-101.
29. Palisano RJ, Hanna SE, Rosenbaum PL, et al. Validation of a model of gross motor function for children with cerebral palsy. Phys Ther. 2000;80:974-985.
30. Russell DJ, Avery LM, Rosenbaum PL et al. Improved scaling of the gross motor function measure for children with cerebral palsy. Phys Ther. 2000;80:873-885.
31. Russell DJ, Rosenbaum PL, Cadman DT, et al. The gross motor function measure: a means to evaluate the effects of physical therapy. Dev Med Child Neurol. 1989;31:341-352.